Effect of clinically significant thresholds of eosinophil elevation on health care resource use in asthma
| Autor: | Sarang Rastogi, Jill Davis, Kathleen M. Fox, Lois Lamerato, Gokul Gopalan, Sameer K. Mathur, Julian Casciano, Zenobia Dotiwala |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male Pulmonary and Respiratory Medicine medicine.medical_specialty Adolescent Immunology Gastroenterology Elevated blood Leukocyte Count Young Adult 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans Immunology and Allergy 030212 general & internal medicine Young adult Aged Retrospective Studies Asthma Aged 80 and over business.industry Retrospective cohort study Health Care Costs Emergency department Middle Aged Patient Acceptance of Health Care Eosinophil medicine.disease United States Eosinophils Hospitalization medicine.anatomical_structure Outpatient visits 030228 respiratory system Resource use Female business Follow-Up Studies |
| Zdroj: | Annals of Allergy, Asthma & Immunology. 125:182-189 |
| ISSN: | 1081-1206 |
| DOI: | 10.1016/j.anai.2020.04.024 |
| Popis: | BACKGROUND Blood eosinophil counts correlate with exacerbations, but there is a lack of consensus on a clinically relevant definition of eosinophil count elevation. OBJECTIVE To analyze health care resource use among patients with elevated blood eosinophil counts defined at 150 cells/μL or greater and 300 cells/μL or greater. METHODS Data on patients who received a diagnosis of asthma between 2007 and 2016 were extracted from EMRClaims + database. Patients were defined as having elevated eosinophil counts if any test result during 3 months before follow-up found blood eosinophil count of 150 cells/μL or more or 300 cells/μL or more. Hospitalizations, emergency department visits, outpatient visits, and associated costs were compared. With logistic regression, likelihood of hospitalization was assessed in the presence of eosinophil elevation. RESULTS Among 3687 patients who met the study criteria, 1152 received a test within 3 months before the follow-up period, of whom 644 (56%) had elevated eosinophil counts of 150 cells/μL or greater and 322 (29%) had eosinophil counts of 300 cells/μL or greater. Overall, the mean (SD) number of hospitalizations for patients with elevated eosinophil counts vs the comparator was significantly greater (0.29 [0.92] vs 0.17 [0.57], P < .001 at ≥150 cells/μL and 0.30 [0.95] vs 0.18 [0.61] at ≥300 cells/μL, P = .001). The total mean cost was significantly greater for patients with elevated eosinophil counts (at ≥150 cells/μL: $10,262 vs $7149, P < .001 and at ≥300 cells/μL: $9966 vs $7468, P = .003). CONCLUSION Patients with asthma incurred greater health care resource use when their blood eosinophil counts were elevated at 150 cells/μL or greater and 300 cells/μL or greater as measured within 3 months of follow-up. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|